MaxCyte Announces Retirement
of Board Member Art Mandell
ROCKVILLE,
MD, December 23,
2024 -
MaxCyte, Inc., (Nasdaq: MXCT; LSE:
MXCT), a leading, cell-engineering focused company
providing enabling platform technologies to advance the discovery,
development and commercialization of next-generation cell
therapeutics, today announced that Art Mandell has retired from his
position as a member of the Board of Directors of MaxCyte effective
December 31, 2024. Mr. Mandell has
served on the Board since 2006 and has been an integral part of
MaxCyte's growth and strategic direction. Upon Mr. Mandell's retirement, MaxCyte will have nine
directors.
During Mr. Mandell's tenure, MaxCyte has achieved
significant milestones including its initial public offering on the
UK AIM exchange and US Nasdaq Listing, the launch of its flagship
ExPERT™ platform, signing 29 Strategic Platform Licenses with cell
and gene therapy biotech companies and supporting the industry's
first, FDA-approved, CRISPR edited non-viral cell therapy.
"We are deeply grateful for Art's exceptional
leadership, scientific insights and valuable contributions over the
years," said Richard Douglas,
chairman of the Board. "Art's perspective
and guidance have been instrumental in positioning MaxCyte as a
leader in cell engineering."
"It has been a privilege to serve on the Board of
MaxCyte," said Mr. Mandell.
"I am proud of all that we have accomplished together, and I am
confident in the Company's bright future providing highly
differentiated technology solutions that enable the development of
novel cell and gene therapies."
About
MaxCyte
At MaxCyte, we pursue cell
engineering excellence to maximize the potential of cells to
improve patients' lives. We have spent more than 25 years honing
our expertise by building best-in-class platforms, perfecting the
art of the transfection workflow, and venturing beyond today's
processes to innovate tomorrow's solutions. Our ExPERT™ platform,
which is based on our Flow Electroporation® technology, has been designed to support
the rapidly expanding cell therapy market and can be utilized
across the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or
disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio. By providing our
partners with the right technology platform, as well as scientific,
technical and regulatory support, we aim to guide them on their
journey to transform human health. Learn more at
maxcyte.com and follow us on
X and
LinkedIn.
MaxCyte
Contacts:
US IR
Adviser
Gilmartin
Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media
Relations
Spectrum Science
Jordan Vines
+1 540-629-3137
jvines@spectrumscience.com
Nominated
Adviser and Joint Corporate Broker
Panmure Liberum
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR
Adviser
ICR
Healthcare
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@icrhealthcare.com
Forward-Looking
Statements
This press release contains
"forward-looking statements" within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995. All statements other than statements of historical
facts contained in this press release, including statements
regarding our future results of operations or financial condition,
business strategy and plans and objectives of management for future
operations, are forward-looking statements. These statements are
inherently uncertain, and investors are cautioned not to unduly
rely on these statements.
Risks and uncertainties related to
our business are described in greater detail in Item 1A of
our Annual Report on Form 10-K for the year ended December 31,
2023, filed with the Securities and Exchange Commission ("SEC") on
March 12, 2024, as well as in discussions of potential risks,
uncertainties, and other important factors in the other filings
that we make with the Securities and Exchange Commission from time
to time, including in our Form 10-Q for the quarter ended September
30, 2024, filed with the SEC on November 6, 2024. These documents
are available through the Investor Menu, Financials section, under
"SEC Filings" on the Investors page of our website at
http://investors.maxcyte.com. Any
forward-looking statements in this press release are based on our
current beliefs and opinions on the relevant subject based on
information available to us as of the date of such press release,
and you should not rely on forward-looking statements as
predictions of future events. We undertake no obligation to update
any forward-looking statements made in this press release to
reflect events or circumstances after the date of this press
release or to reflect new information or the occurrence of
unanticipated events, except as required by law.